Naim Alkhouri

20.5k total citations · 15 hit papers
325 papers, 11.2k citations indexed

About

Naim Alkhouri is a scholar working on Epidemiology, Hepatology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Naim Alkhouri has authored 325 papers receiving a total of 11.2k indexed citations (citations by other indexed papers that have themselves been cited), including 257 papers in Epidemiology, 162 papers in Hepatology and 81 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Naim Alkhouri's work include Liver Disease Diagnosis and Treatment (251 papers), Liver Disease and Transplantation (91 papers) and Diet, Metabolism, and Disease (71 papers). Naim Alkhouri is often cited by papers focused on Liver Disease Diagnosis and Treatment (251 papers), Liver Disease and Transplantation (91 papers) and Diet, Metabolism, and Disease (71 papers). Naim Alkhouri collaborates with scholars based in United States, United Kingdom and Italy. Naim Alkhouri's co-authors include Ariel E. Feldstein, Rocío López, Mazen Noureddin, Stephen A. Harrison, Valério Nobili, Nizar N. Zein, Laura J. Dixon, Arun J. Sanyal, Christine Carter‐Kent and Anna Alisi and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Naim Alkhouri

294 papers receiving 11.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

2019 536 citations Stephen A. Harrison, Mustafa R. Bashir et al. profile →
NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances

2018 439 citations Mazen Noureddin, Tsuyoshi Todo et al. profile →
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH

2023 271 citations Rohit Loomba, Arun J. Sanyal et al. profile →
Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials

2020 263 citations Stephen A. Harrison, Naim Alkhouri et al. Journal of Hepatology profile →
Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial

2023 234 citations Stephen A. Harrison, Rebecca Taub et al. profile →
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis

2024 217 citations Mandy Fraessdorf, Guy Neff et al. profile →
Challenges and opportunities in NASH drug development

2023 208 citations Stephen A. Harrison, Mazen Noureddin et al. profile →
Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis

2021 203 citations Tavankit Singh, Srinivasan Dasarathy et al. profile →
Therapeutic pipeline in nonalcoholic steatohepatitis

2021 198 citations Raj Vuppalanchi, Mazen Noureddin et al. profile →
Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort

2021 172 citations Stephen A. Harrison, Samer Gawrieh et al. Journal of Hepatology profile →
Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement

2021 163 citations Naim Alkhouri et al. profile →
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial

2022 157 citations Naim Alkhouri, Anita Kohli et al. Journal of Hepatology profile →
Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study

2023 88 citations Manal F. Abdelmalek, Naim Alkhouri et al. Clinical Gastroenterology and Hepatology profile →
Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis

2024 55 citations Mazen Noureddin, Meena B. Bansal et al. Clinical Gastroenterology and Hepatology profile →
Estimated Burden of Metabolic Dysfunction–Associated Steatotic Liver Disease in US Adults, 2020 to 2050

2025 55 citations Phuc Le, Srinivasan Dasarathy et al. profile →

Peers

Countries citing papers authored by Naim Alkhouri

Since Specialization

Citations

This map shows the geographic impact of Naim Alkhouri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naim Alkhouri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naim Alkhouri more than expected).

Fields of papers citing papers by Naim Alkhouri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naim Alkhouri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naim Alkhouri. The network helps show where Naim Alkhouri may publish in the future.

Co-authorship network of co-authors of Naim Alkhouri

This figure shows the co-authorship network connecting the top 25 collaborators of Naim Alkhouri. A scholar is included among the top collaborators of Naim Alkhouri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naim Alkhouri. Naim Alkhouri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effects of Resmetirom on Metabolic‐Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon‐Like Peptide‐1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO ‐ NASH Trial 2025 ·Alimentary Pharmacology & Therapeutics ·Mazen Noureddin, Mary E. Rinella, Rebecca Taub, Dominic Labriola, Raul C. Camacho, Naim Alkhouri, Rohit Loomba, Meena B. Bansal	2
2	MetALD: New Perspectives on an Old Overlooked Disease 2025 ·Liver International ·Gustavo Ayares, Luis Antonio Díaz, Francisco Idalsoaga, Naim Alkhouri, Mazen Noureddin, Ramón Bataller, Rohit Loomba, Juan Pablo Arab, Marco Arrese	4
3	The trends and incidence of alcohol-associated hepatitis hospitalizations from 2016–2020 and the impact of the COVID-19 pandemic 2024 ·Alcohol ·(unknown), Pooja Rangan, Naim Alkhouri, Jessica L. Mellinger, Karn Wijarnpreecha	0
4	The effect of vitamin E and docosahexaenoic acid ethyl ester on Metabolic Dysfunction‐Associated steatotic Liver Disease (MASLD)—A randomised, double‐blind, placebo‐controlled, parallel‐group clinical trial (PUVENAFLD) 2024 ·Alimentary Pharmacology & Therapeutics ·Naim Alkhouri, Deanna McCarthy, (unknown), Traci M. Blonquist, Karin Yurko‐Mauro, Raj Vuppalanchi, Eric Lawitz, Naga Chalasani	3
5	Management strategies for metabolic dysfunction–associated steatotic liver disease (MASLD) 2024 ·The American Journal of Managed Care ·Naim Alkhouri, Mazen Noureddin	7
6	WED-212 Pemvidutide treatment is associated with improvement in non-invasive tests indicating greater likelihood of histologic response in subjects with metabolic dysfunction-associated steatotic liver disease: a 24-week, randomized, double-blind, placebo-controlled trial 2024 ·Journal of Hepatology ·Naim Alkhouri, Shaheen Tomah, John J. Suschak, (unknown), M. Scot Roberts, (unknown), Sarah Browne, Rohit Loomba	1
7	Su1537 MACHINE LEARNING ADVANCED FIBROSIS AND AT-RISK MASH (ALADDIN) WITH A WEB-BASED CALCULATOR FOR PROBABILITY PREDICTION 2024 ·Gastroenterology ·Winston Dunn, Naim Alkhouri, Terry Cheuk‐Fung Yip, Laurent Castéra, Vincent W. S. Wong, Grace L. Wong, (unknown), (unknown), Ajay Duseja, (unknown), Stephen A. Harrison, Juan Pablo Arab, Syed‐Mohammed Jafri, Ashwani K. Singal, Vincent Chen, Luis A. Díaz	2
8	Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH 2024 ·Liver International ·Naim Alkhouri, (unknown), Jeffrey E. Edwards, Fred Poordad, Eric Lawitz, Lois K. Lee, (unknown), Sangeeta Sawhney, Mary Erickson, Leigh MacConell, Luna Zaru, (unknown), Jason Campagna	10
9	Mortality outcomes in individuals with MASLD versus MASLD and increased alcohol intake 2024 ·Journal of Gastroenterology and Hepatology ·Majd B. Aboona, Pojsakorn Danpanichkul, Vincent Chen, Pooja Rangan, Donghee Kim, Naim Alkhouri, Michael B. Fallon, Mazen Noureddin, Juan Pablo Arab, Karn Wijarnpreecha	12
10	Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis 2024 ·Journal of Hepatology ·Eric Lawitz, Mandy Fraessdorf, Guy Neff, Jörn M. Schattenberg, Mazen Noureddin, Naim Alkhouri, Hans Bernhard Schmid, Charles P. Andrews, István Takács, Samina Ajaz Hussain, Wiebke Fenske, Edward Gane, Azadeh Hosseini‐Tabatabaei, (unknown), Daniel Ferraz de Campos Mazo, Ramy Younes	25
11	Artificial Intelligence Applications in Hepatology 2023 ·Clinical Gastroenterology and Hepatology ·Jörn M. Schattenberg, Naga Chalasani, Naim Alkhouri	21
12	Prevalence of at-risk NASH and its association with metabolic syndrome in US adults with NAFLD, 2017–2018 2023 ·Hepatology Communications ·(unknown), Naim Alkhouri, Phuc Le, Michael B. Rothberg, (unknown), (unknown), Srinivasan Dasarathy	21
13	The use of current knowledge and non‐invasive testing modalities for predicting at‐risk non‐alcoholic steatohepatitis and assessing fibrosis 2023 ·Liver International ·Marcelo Kugelmas, Mazen Noureddin, Nadege Gunn, Kimberly Brown, Zobair M. Younossi, Manal F. Abdelmalek, Naim Alkhouri	12
14	Increased accuracy in identifying NAFLD with advanced fibrosis and cirrhosis: independent validation of the Agile 3+ and 4 scores 2023 ·Hepatology Communications ·Mazen Noureddin, Edward Mena, Raj Vuppalanchi, Niharika Samala, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Nabil Noureddin, Anita Kohli, Stephen Harrison, Samer Gawrieh, Naim Alkhouri, Emily Truong	24
15	Accuracy of noninvasive fibrosis scores in predicting advanced fibrosis in pediatric patients after liver transplantation 2022 ·Pediatric Transplantation ·(unknown), (unknown), (unknown), Praveen Kumar Conjeevaram Selvakumar, Rocío López, Naim Alkhouri, Mohammad Nasser Kabbany	2
16	A practical use of noninvasive tests in clinical practice to identify high‐risk patients with nonalcoholic steatohepatitis 2022 ·Alimentary Pharmacology & Therapeutics ·Zobair M. Younossi, Naim Alkhouri, (unknown), (unknown), Fasiha Kanwal, Mazen Noureddin, Rohit Loomba, Natarajan Ravendhran, Brian Lam, (unknown), Andrei Racila, Fatema Nader, Linda Henry	22
17	Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH 2022 ·Journal of Hepatology ·Vlad Ratziu, Stephen A. Harrison, V. Loustaud‐Ratti, Christophe Bureau, Eric Lawitz, Manal F. Abdelmalek, Naim Alkhouri, Sven Francque, (unknown), Raphaël Darteil, (unknown), Myles Wolf, Arun J. Sanyal, Jacky Vonderscher, Piétro Scalfaro	73
18	Biomarkers, imaging and safety in resmetirom 52 week non-cirrhotic NASH phase 3 clinical trial, completed open-label arm of maestro-NAFLD-1 2022 ·Digestive and Liver Disease ·Stephen A. Harrison, (unknown), (unknown), (unknown), Rebecca Taub, Guy Neff, Naim Alkhouri, Mustafa R. Bashir	1
19	MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis 2021 ·Journal of Hepatology ·Mazen Noureddin, Emily Truong, Jeffrey Gornbein, Rola Saouaf, Maha Guindi, Tsuyoshi Todo, Nabil Noureddin, Ju Dong Yang, Stephen A. Harrison, Naim Alkhouri	117
20	Sofosbuvir‐based treatment is safe and effective in patients with chronic hepatitis C infection and end stage renal disease: a case series 2016 ·Liver International ·Tavankit Singh, John Guirguis, (unknown), (unknown), Ibrahim A. Hanouneh, Naim Alkhouri	41

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact